Neosporin Market Report: Sales Volume, Market Share, Leading Brands & Market Trends

LUMIFY is the best-performing neosporin brand in July 2026, moving 100,000 units across 1 ASIN for 40.2% of Top 10 volume. Neosporin follows with 60,000 units (24.1%), ahead of Johnson & Johnson on 40,000 units (16.1%).

With 8 brands splitting the Top 10 and 80.3% of volume sitting with three of them, this is a concentrated shelf — the leaders hold multiple listings or one very high-velocity ASIN, so a new entrant competes against established review moats rather than an open field. Average selling prices among the leaders run from $4.88 to $11.93, which frames the price band a competing listing has to justify.

Based on July 2026 data, this shortlist surfaces the two kinds of ASIN worth keeping an eye on — the ones that just broke into the Top 10, and the ones growing fastest month over month. Specifically, one ASIN forced its way in: B09WSTBRBN booked 9K units at $6.58, with ▲ 0.0% MoM change. On the growth side, B07GPSQHB4 leads positive momentum with ▲ 200.0% MoM growth on 3K units, with B08SJKPLJS close behind at ▲ 100.0% MoM on 2K units.

The two signals carry different weight. A fresh entrant means share has already changed hands — an incumbent gave up its place to make room, so any competitive set drawn up a month ago is now out of date. A steep growth rate works as the earlier warning: it marks demand that is still compounding, usually a month or two before the ranking catches up to it.